By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its third-quarter revenues jumped 25 percent and its non-GAAP net income more than doubled on strong clinical sales.

The Sunnyvale, Calif.-based molecular diagnostics firm brought in total revenues of $70.2 million for the three months ended Sept. 30, compared to $56.1 million for the third quarter of 2010. It beat analysts' consensus estimate for revenues of $68.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.